Markets

SiteOne® Landscape Supply, Inc. (NYSE: SITE), the largest and only national wholesale distributor of landscape supplies in the United States, today announced that management will participate in the following investor conferences: Zelman & Associates 2020 Virtual Housing Summit on Tuesday, September 22, 2020. William Blair’s “What’s Next For Industrials” Conference on Thursday, September 24, 2020. About SiteOne Landscape Supply: SiteOne Landscape Supply, Inc. is the largest and only national wholesale distributor of landscape supplies in the United States and has a growing presence in Canada. Its customers are primarily residential and commercial landscape professionals who specialize in the design, installation and maintenance of lawns, gardens, golf courses and other outdoor spaces. View source version on businesswire.com: https://www.businesswire.com/news/home/20200918005489/en/

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST. The mini-oral presentations, titled “Clinical Benefit with Ripretinib as =4th Line Treatment in Patients with Advanced Gastrointestinal Stromal Tumors (GIST): Update from the Phase 3 INVICTUS Study” and “Ripretinib Intra-patient Dose Escalation (IPDE) Following Disease Progression Provides Clinically Meaningful Progression-Free Survival (PFS) in Gastrointestinal Stromal Tumor (GIST) in Phase 1 Study”, were featured at the ESMO Virtual Congress 2020 being held September 19-21, 2020. “As the body of data supporting QINLOCK’s efficacy and safety grows, we are pleased with QINLOCK’s ability to offer clinically meaningful benefit for GIST patients across multiple lines of therapy,” said Matthew L. Sherman, MD, Executive Vice President and Chief Medical Officer of Deciphera. “Data presented today demonstrates impressive long-term, follow-up results from our INVICTUS study, which support QINLOCK’s efficacy in fourth-line GIST.” INVICTUS Additional Nine Month Follow-up Data The INVICTUS Phase 3 clinical study is a randomized (2:1), double-blind,

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for =24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatments. This means patients with progressive NETs are able to remain on a more tolerable first-line standard of care for longer,” said Professor Marianne Pavel, Friedrich-Alexander University of Erlangen, Germany, Senior Physician and Chair of Endocrinology, and lead investigator of the study. Lanreotide is a synthetic form of a natural hormone called somatostatin and is

ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, today introduces the industry’s thinnest dedicated sensor for blood oxygen saturation (SpO2) measurement, bringing the capability to remotely monitor this vital sign to small consumer products such as earbuds, smart watches and wristbands, as well as to medical devices such as patches and oximeters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005408/en/ ams press picture AS7038RB (photo credit: ams AG) The high performance of the new AS7038RB also means that it is suitable for innovative applications in remote diagnostic equipment, such as disposable patches used for SpO2 and electro-cardiogram (ECG) measurement in hospital emergency rooms. This gives medical teams and patients greater flexibility to choose how, where and when measurements of these vital signs are taken using non-invasive methods for fast response. In fact, a growing body of evidence suggests that low SpO2 is an early symptom of the COVID-19 disease before the onset of breathing difficulty in some at-risk patients. The development of a wearable SpO2 measurement device based on the AS7038RB can be used remotely and therefore help in the treatment of people infected with the SARS-CoV-2 virus. Wim

Talem Health Analytics, a leading provider of bodily injury causation solutions, and Guidewire Software, Inc. (NYSE: GWRE), the platform P&C insurers trust to engage, innovate, and grow efficiently, today announced that Talem Health Analytics has joined Guidewire PartnerConnect as a Solution partner. Using evidence-based research combined with machine learning and AI technology, Talem Health Analytics (Talem) works to empower insurers with an enhanced understanding of injury causation and medical recovery from the start of the claims process. Talem delivers an objective, scientific analysis of the injury and injury causation, as well as providing specific claim recommendations and action points for the adjuster. “Our mission is to demonstrate that technology advances insurance instead of disrupting it,” said Matthew Kay, chief operating officer, Talem Health Analytics. “Insurers can leverage our injury causation analysis to make informed decisions and establish a transparent and consistent narrative early on, decreasing overall medical claims costs, highlighting medical fraud, and increasing efficiency. We are pleased to partner with Guidewire to bring these benefits to our joint customers” “We are delighted to welcome Talem Health Analytics to Guidewire PartnerConnect as a Solution partner,” said Becky Mattick, vice president, Global Solution Alliances, Guidewire Software. “Talem’s injury

Semtech Corporation (Nasdaq: SMTC), a leading supplier of high performance analog and mixed signal semiconductors and advanced algorithms, announced that JAM-Labs, a leading solutions provider for the healthcare, digital signage and Pro AV markets, has integrated Semtech’s BlueRiver® technology into its new line of Software Defined Video over Ethernet (SDVoE™)-enabled integrated operating room (OR) products. The products, based on the BlueRiver AVP ASIC, enable state-of-the-art medical facilities to capture and transmit high quality 4K60P 4:4:4, near-zero latency SDVoE video. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200917005011/en/ JAM-Labs leverages Semtech’s BlueRiver (Photo: Business Wire) “ORION 4K end points enhance its integration capabilities using Semtech’s BlueRiver for digital operating rooms. Using the ORION end points and workflows based on enhanced secure software integration, hospitals are able to realize 4K video with near-zero latency over networks, bringing a truly distributed solution to life,” said John Thomas, CEO and CTO at JAM-Labs. “Semtech’s BlueRiver technology is at the heart of the ORION system. With standards-based SDVoE capabilities, we are able to offer a completely vendor neutral solution with an open, scalable architecture platform versus legacy matrix switch systems.” JAM-Labs’ ORION is certified to IEC60601 and compliant to

Simmons Energy I A Division of Piper Sandler (Simmons) is pleased to announce the addition of Doug Reynolds and Robert Urquhart as managing directors within the energy investment banking group. Both Reynolds and Urquhart will be based in the firm’s Houston office and will focus on exploration and production (E&P). Reynolds brings over 30 years of experience in energy investment banking. Prior to joining the firm, Reynolds was formerly head of U.S. energy corporate and investment banking at Scotiabank. Prior to that, he was the head of U.S. upstream investment banking at the Macquarie Group. Earlier in his career, Reynolds worked at Banc of America Securities, Credit Suisse and Salomon Brothers. Reynolds earned a bachelor’s degree in economics from Colgate University. Urquhart brings over 10 years of experience in energy investment banking. Prior to joining the firm, Urquhart was a managing director within the energy investment banking group at Scotiabank, where he focused primarily on E&P. Prior to that, he was an associate at Madison Williams and a Portfolio Manager at PEAK6 Investments. Urquhart earned a bachelor’s degree in political economics from Princeton University and a Master of Business Administration in finance and accounting from the University of

As a leader in respiratory viral and bacterial testing, Eurofins Diatherix is pleased to announce the development of Flu Plus, a new test added to its proprietary respiratory testing portfolio. Specimens have been accepted for testing as of 10 September 2020. Diatherix received Emergency Use Authorization from the FDA for their SARS-CoV-2 virus test on 22 April 2020. Eurofins laboratories (including Diatherix) have completed over one million COVID tests to date in the US, and are pleased to leverage extensive respiratory and infectious disease expertise to continue to assist clinicians in their response to COVID-19. To this end, Diatherix has developed the Flu Plus test which includes the unmodified EUA approved SARS-CoV-2 virus along with five additional viral pathogens which can be used to assist healthcare providers with the accurate identification of the most prevalent viruses associated with respiratory illnesses. These five viral pathogens include Influenza A, A(H1N1)pdm09, Influenza B, Respiratory Syncytial Virus (A&B), and Human Rhinovirus/Enterovirus which can be known to exacerbate the recovery for high-risk patients. This new test complements Diatherix’s existing testing options for COVID-19, which includes the SARS-CoV-2 single target test, our unique COVID-19 test which offers the SARS-CoV-2 virus plus 5 additional synergistic

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced today that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200912005013/en/ Enrollment in the trial has been proceeding as planned and the company expects to reach its initial target of up to 30,000 participants next week. The proposed expansion would allow the companies to further increase trial population diversity, and include adolescents as young as 16 years of age and people with chronic, stable HIV (human immunodeficiency viruses), Hepatitis C, or Hepatitis B infection, as well as provide additional safety and efficacy data. The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing. As stated previously, based on current infection rates, the companies continue to expect that a conclusive readout on efficacy is likely by the end of October. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to

Western Union, a global leader in cross-border, cross-currency money movement and payments, and the Western Union Foundation have announced the Foundation’s pledge of USD 250K in relief to support the immediate and long term recovery needs of refugees including the people displaced from Greece’s Moria Camp. More than 12,000 people have been evacuated from the Moria Camp on the island of Lesbos, which was destroyed by fires earlier this week. The camp was the temporary home to migrants, refugees and asylum seekers from more than 70 different countries, among them elderly, pregnant women, children, and people with disabilities. With a fire devastating their only place of refuge, thousands are now without shelter and access to water and sanitation. The Foundation will deploy USD 100K to support the International Rescue Committee (IRC) in their immediate relief efforts for the Moria camp evacuees. Funds will support secure accommodations, mental health and psychosocial support, and distribution of urgent supplies, with a focus on safety to avoid the risk of COVID-19 transmission. An additional USD 150K in funding will support longer-term advocacy and relief efforts to enable sustainable living for refugees in Greece. “Western Union and our Foundation are unrelenting in